Sept 27 (Reuters) - Savara Inc :
* SAVARA ANNOUNCES EXPANDED ACCESS PROGRAM (EAP) FOR MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) FOR PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)
* SAVARA : SAVARA EARLY ACCESS ACCEPTING REQUESTS FROM PATIENTS IN SELECT COUNTRIES IN N.AMERICA & EUROPE, PLANS TO EXPAND THROUGH 2026
* SAVARA INC: PLANS TO COMPLETE SUBMISSION OF A BLA TO FDA FOR MOLGRAMOSTIM IN APAP IN H1 OF 2025
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。